narrow-moat cooper report healthi fiscal year
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
cash-pay busi sticki custom competitor
contact len industri attract market opinion
accord four largest player johnson johnson
novarti valeant control approxim
global market industri regul creat strong barrier
think coopervis long-term outlook rel healthi
even though concern increas competit
specialti len market benefit higher-pr product
offer silicon hydrogel one-day premium lens
expect expand margin maintain earn growth
outpac growth overal soft contact len market
believ len sale growth driven two key
factor first see increas adopt contact lens
world-wide larg emerg market unpreced rise
myopia particularli under-penetrated asian market
present long-term growth opportun histor adopt
rate second believ exist custom trade
premium product daili dispos lens grow
popular across globe coopervis expand portfolio
well posit benefit key driver
one fourth total revenu acquisit paragard
nonhormon copper iud expect paragard
continu propel segment toward outsiz growth
opinion paragard well posit benefit secular trend
toward increas adopt iud monopoli
nonhormon highli regul iud space expect
segment continu experi double-digit growth
next five year expect iud usag rate
mirror rate develop countri lead market
satur slowdown segment revenu growth
anticip continu invest surgic
segment increas sale effort paragard well
tuck-in acquisit histor strategi
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cooper compani oper two unit coopervis coopersurg
account approxim total sale coopervis
second largest player oligopolist contact len market
coopervis sale intern territori second unit
coopersurg develop manufactur diagnost surgic
product gynecologist obstetrician includ paragard iud
acquir teva
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
narrow-moat cooper report healthi fiscal
compani releas strong fourth-quart full-
year result experienc growth revenu
respect
slightli manag
guidanc line expect also
benefit pronounc oper margin expans
increas full-year margin
basi remain stabl pro forma
basi differ metric larg attribut
relat
acquisit integr activ accordingli may
rais fair valu estim slightli account
expans howev underli view narrow-moat
compani competit advantag moati
contact iud space abl innov
distinguish nich high regulatori barrier
entri remain unchang manag provid
guidanc companywid sale growth
vision segment rang estim roughli higher
project rang surgic segment notabl
manag warn investor expect soft
first quarter due buy-in activ associ
paragard price
increas manufactur
shakeout vision segment
cooper vision segment grew fourth quarter
year continu led robust
growth attract daili silicon hydrogel len
space growth asia-pacif region almost
doubl second fastest grow geograph
segment america grew fourth
quarter notabl receiv fda approv ahead
schedul novemb innov misight product
myopia near-sight manag product
target address issu children
product first kind manag
estim underserv market could worth
multibillion dollar target launch
misight product march target
corpor spend estim million
million manag expect
spend translat roughli million sale
million sale anticip stem
 potenti doubl size year come
howev temper expect cooper
manufactur sever innov product
anticip mitig year howev still expect
constraint persist fiscal year
capac constraint
suffer
surgic segment revenu increas
fourth quarter paragard grow manag
accredit lower-than-averag perform
multi-year averag sell price increas around
addit manag pull televis advertis
product notabl campaign new york citi
metro area comment believ
campaign success translat top-lin momentum
plan focu less costli advertis method
aim smaller dispers market fertil revenu
growth quarter buoy segment led
high ivf consum sale howev still view
segment competit advantag sole relat
paragard product signific differenti
nonhormon iud approv iud
approv longest durat remain optimist
product growth potenti
rais fair valu estim per share
base belief contact len market
continu experi strong growth emerg
market benefit consum trading-up satur
market addit anticip impress growth
momentum paragard continu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
addit paragard coopersurg portfolio
expect segment contribut high-single-digit growth
boost companywid gross margin bake
low-double-digit growth paragard product
segment project think product benefit
shift famili plan prefer demograph
dynam improv safeti percept among
obstetrician consum inform
estim iud market doubl
adopt rate converg usag rate
rest develop world think iud market
exceed billion think paragard
nonhormon opinion possess around
share initi adopt growth phase sinc
paragard long-us life women
replac product think revenu grow
less slightli exceed popul growth
rate woman cohort peak
revenu approxim million doubl
estim current sale contribut
think rel stabl market share modest
increment growth econom stabil cash-pay
natur contact len market support medium
uncertainti rate
bullish scenario assum greater proport
sale firm myday clariti daili contact lens
market share gain len segment steadi growth
surgic segment increas five-year compound-annual-growth-rate
base case scenario
assum oper margin expand daili
lens carri high gross profit dollar term compar
modal margin seem like improv
growth rate daili silicon hydrogel lens higher
expect case strength paragard
rest surgic busi accret gross margin
expect shift toward favor product mix
serv expand companywid margin valuat
time
expect on-going adopt silicon
hydrogel product combin custom upgrad
daili dispos lens drive firm five-year
compound annual growth rate believ margin
expans drive even faster earn growth
manufactur yield improv custom continu
switch higher-pr daili dispos lens assum
increas manufactur effici contact lens
expand oper margin
achiev landmark becom
second-largest len compani market share world-wide
though believ unlik
challeng johnson jonson lead posit expect
surg ahead widen gap
two major industri player
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
start contribut larger proport sale
assumpt arriv fair valu estim
bear case assum sale growth slow
five-year compound-annual-growth-rate oper margin
result fair valu estim could occur
stumbl incorpor anoth acquisit
face greater-than-expect declin surgic
lens-car busi due competit pressur
unexpect shift consum prefer
oligopolist contact len industri narrow moat due
intang asset oper high switch
cost space hold roughli share global
contact len market exceed johnson johnson
combin alcon valeant
bausch lomb compani make
global contact len market contact manufactur
shield barrier entri vision-car market
allow firm produc consist econom profit
expect materi chang contact len adopt
overal given contact len market grow faster
overal eyewear market
inconveni eyeglass complic
expens associ correct surgeri
opinion regul natur contact len
first lens must approv regul
 food drug administr typic
patent protect exampl coopervis patent
aquaform technolog aquaform high oxygen
transmiss low modulu keep len
softer flexibl coopervis
competitor second current law patient must visit
licens optometrist new exam purchas
contact lens must get prescript renew everi
time need order new suppli prescript
brand-specif requir new entrant build
level trust medic commun doctor
hesit embrac new product
proven record safeti often receiv rebat
manufactur necessit optometrist visit lead
optometrist recommend establish brand
bolster coopervis contact len oligopoli
addit believ coopervis competit
sustain high switch cost
environ consum physician side contact
len sale custom content optometrist
receiv coverag eye exam unlik
switch contact differ manufactur
accord inform technolog innov
institut optometrist primarili prescrib one
manufactur contact prescript brand
mean switch optometrist lead
averag consum stay lens upward
seven year also custom comfort
product unlik chang lens minor
improv small reduct price contact lens
suppli
strong relationship manufactur
like chang brand len prescrib given
custom larg due familiar product
safeti consider incent structur
mani optometrist receiv manufactur rebat
tie practic sale volum specif
manufactur contact lens larg paid
pocket coopervis larg unaffect pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
insur seen ration price prevail
past decad expect price war
cooper vision togeth account
contact set similar price floor mani
contact prevent larg on-line discount retail
alter competit landscap addit manufactur
contact lens capital-intens complic
process creat cost advantag top four
len manufactur though provid
uniqu advantag given high up-front cost
difficulti captur new custom exist brand
anticip new entrant space
believ coopersurg overal sale
fiscal produc medic devic relat
women health contribut narrow econom
moat paragard iud product believ paragard
benefit regulatori intang asset conjunct
possess advantag element effici
scale oper ration monopoli limit
market believ coopersurg moat
relat product primarili
commodity-lik surgic suppli fertil offer
numer establish competitor
space johnson johnson boston scientif
coopersurg growth larg driven heavi
 activ includ firm billion acquisit
teva paragard iud believ
manag expans segment portfolio
recent year oper wise term cash
flow manag strateg smart term
paragard although think coopersurg
coopervis benefit cost synergi given
busi dispar natur
coopersurg
alreadi exist
relationship obstetrician women health
profession market paragard
believ paragard benefit high regulatori
barrier entri surround iud market
discourag potenti entrant cost
manufactur clinic trial market talli
prohibit anoth market entrant nich
space stringent regul iud uniqu
put place respons litigi
dalkon shield iud incid approv iud caus
sever reaction death hundr women
subsequ fda made decis regul iud
drug rather medic devic even iud
nonhormon use copper activ ingredi
drug much costlier lengthi
approv process medic devic much
addit contracept drug oral
contracept garner reoccur revenu
like provid greater overal profit
manufactur even though iud tend higher
up-front payer cost paragard effect longev make
least expens iud per usag year take
averag year achiev cost neutral compar
pill patch ring paragard approv
year usag period iud also tend litigi product
unless market decad
proven safeti record paragard riski
addit drug manufactur product portfolio
direct reput cost larg pharmaceut
compani would capit risk capac
potenti develop iud may weari
rel limit upsid neg reput
effect litig could sale
moreov larg respons neg safety-rel
percept surround iud linger
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
dalkon shield iud market remain rel
small comparison market paragard
benefit element effici scale advantag
base posit virtual ration monopoli
nonhormon iud space exampl iud account
contracept market versu
asia paragard current make
market thu though see billion iud market
grow rapidli believ nonhormon portion
abl serv entir paragard low
margin cost due high margin natur like
lower distribut cost healthcar provid
consolid awar iud current
develop pipelin believ time
potenti entrant would abl get new iud offer
approv growth substanti slow
unlik entrant abl sustain econom
profit incur larg market cost fierc
competit establish competitor furthermor
element credibl deterr new entrant
market given distinct separ busi
segment given primari revenue-driv
vision segment strateg altern
attract accommod new rival could suffer
temporari loss segment aim forc new
entrant potenti entrant would
also believ paragard histor slow growth
teva support belief paragard benefit aspect
oper effici scale market anticip
becom satur near term
prohibit fix cost make unviabl market
competitor enter paragard iud
market longest durat sinc
virtual stagnat experienc littl growth decad
prior acquir
began spend larg sum market paragard even
establish product start grow averag
last five quarter highlight
import awar salesforc interact
clinician sell iud believ cooper
larg advertis spend salesforc mobil yet
anoth cost make unlik new competitor
attempt enter iud space especi
unlik
award stabl moat trend vision
surgic segment sinc launch silicon hydrogel
len portfolio maintain gain market
share categori lens still expect
materi chang competit dynam among cooper
three major len manufactur think
barrier entri substanti enough preclud new
competitor enter market cost
stabl believ custom remain unlik
switch brand contact lens base margin
chang qualiti price dynam cooper
continu make concert effort maintain key
relationship optometrist addit cooper
commit expand geograph reach
expand portfolio len modal specialti lens
help gain market share rel alcon bausch
 lomb though histor
innov leader firm late game
silicon hydrogel product risk behind
curv futur innov briskli regain
market share later come one
complet suit silicon hydrogel product capit
weak alcon bausch lomb
impress rebound inspir us renew
confid innov prowess bolster
confid abil defend competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
although firm invest widen surgic
segment ivf fertil portfolio competit women
health among devic maker remain fierc
unlik chang
advantag strong innov pipelin gain
share first market captur subsequ
advantag key product area myopia
manag opinion abil quickli
regain lost ground highlight stabil industri
establish player addit novarti recent
spun alcon busi valeant balloon debt
creat uncertainti ophthalmolog segment
coopervis
control lion share industri give firm
price power peer
think coopersurg competit posit
materi chang either think paragard
competit intang asset advantag stem
first-mov advantag iud market conjunct
high barrier entri owe strict regul
iud space limit appeal potenti entrant due
rel small market remain stabl even though
 iud market grow unlik new
entrant space think improb women
current use bayer hormon option prefer
benefit hormon iud switch prefer
nonhormon option bayer virtual
competitor iud space offer
uniqu differenti nonhormon product come
benefici attribut predict paragard
gain minim market share hormon iud
market howev think retain proport
grow market recent iud market growth
due increas women use
contracept rather attribut shift
market mix toward long-term effect option
consum
demograph prefer also anticip
regulatori reimburs space chang base
histor preced exclud paragard think
exogen chang
due
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ocoopervis benefit custom trade
weekli monthli contact lens expens
oa signific portion revenu come
foreign currenc leav compani suscept
chang exchang rate
ocontinu trade-up trend silicon hydrogel
drive growth firm len busi
oparagard nonhormon iud approv
 seriou competit
ocoop competitor larger divers
revenu stream allow greater research
laggard bring silicon hydrogel
lens market indic potenti
innov leader
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ solid financi strength
compani took billion debt fiscal acquir
teva paragard iud vision surgic segment
gener enough cash allow compani
pay debt continu invest busi
histor troubl pay debt
debt/ebitda fiscal end
fiscal even larg acquisit signific
uptick market cost firm complet
debt time ebitda even addit leverag
anticip challeng meet
oblig given sticki custom minim
econom sensit contact len market alreadi
extrem consolid especi sauflon
acquisit futur larg acquisit seem unlik
coopervis firm may seek addit capit
pursu bolt-on deal surgic divis coopersurg
acquir compani sinc project
continu
cash-pay natur contact len market support
medium uncertainti rate cooper opinion
largest risk face oper consolid
market requir top player act ration
top len manufactur mandat retail sell
product minimum price lead
almost retail set respect price
price floor though manufactur offer volume-bas
rebat optometrist foster clinician brand loyalti
manufactur receiv regulatori scrutini
around practic claim amount unfair
price set though predict disrupt
price system ftc regulatori entiti deem
unfair trade practic would like
larg neg impact price power len
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market larg on-line discount retail would like
compet fierc price opinion coopersurg
face risk relat healthcar polici reform
specif relat afford act
paragard product aca contracept
coverag mandat dictat privat insur
provid medicaid must cover iud without cost
share bring median out-of-pocket cost
consum sinc paragard approv
nonhormon iud paragard mandatorili cover
wide cover iud market therefor
repeal mandat could neg impact iud adopt
paragard sale howev though
substanti uptick iud usag post-aca import
note usag rate alreadi trend upward prior
thu even portion
repeal like iud usag would take stark
dive insur previous cover larg portion
iud cost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
share
fund
share
fund
manag behind innov curv vision
care invest enough develop silicon
hydrogel lens howev coopervis sinc regain
lost ground quickli adapt market trend
focus specialti lens addit believ
manag kept sound merger acquisit
polici segment opinion done
commend job recent year build vision
product portfolio expand global market share
histor manag larg use excess capit
bolt-on acquisit except
acquisit sauflon billion recent
billion acquisit paragard believ benefit
sauflon deal outweigh associ expens
oper difficulti firm face year
follow acquisit firm use acquisit
support moat vision care enter
mass-market hydrogel space financ paragard
acquisit ad billion debt balanc
sheet also ad steadi high-margin busi
expand surgic divis product portfolio though
would like see manag make effort divest
product offer histor
dampen return surgic segment believ
manag respons run two dispar
segment coopervis coopersurg alloc
cash flow new opportun come
industri acquisit paragard iud serv
promin exampl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
like futur trajectori product
belief found fact iud adopt
continu grow manag seem intent
drive concert effort capit trend
announc plan rais averag sell price
least would still mean paragard retain
attract statu cheapest iud option
year revenu increas rel flat oper
gross margin pro forma basi taken
fresh look companywid segment level
accordingli rais estim fair valu
approxim per share per share
increas primarili due belief
competit advantag surgic strengthen due
regulatori dynam surround
high-margin
paragard product optim surround market
potenti misight product invigor
overal confid abil innov
maintain strong competit foot vision segment
though companywid pro forma margin expand
quarter forecast signific futur improv buoy
continu manufactur effici vision coupl
growth paragard ramp market
expens expect favor impact cooper
gross oper margin respect
report pro forma growth vision segment
propel outsiz growth toric daili sphere lens
low-double-digit growth asia-pacif market
reinforc manag thesi growth
contact segment primarili spur increas
adopt emerg market mix shift premium
daili develop market addit see larg
upsid potenti myopia manag product
first kind shown impress momentum
region launch manag allud
may receiv fda approv end calendar year
surgic revenu grew quarter
expect partial due flat growth
paragard expect product fair better
think quarter perform indic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
